Boehringer Ingelheim Expands Oncolytic Virus Efforts With ViraTherapeutics Buy

 
• By Kevin Grogan

Paying €210m for a company that only has preclinical programs may seem steep but BI is clearly impressed with the progress being made by its Austrian partner's lead candidate.

Carousel
BI jumps onto the I-O M&A merry-go-round • Source: Shutterstock

More from Immuno-oncology

More from Anticancer